Real-world clinical multi-omics analyses reveal bifurcation of ER-independent and ER-dependent drug resistance to CDK4/6 inhibitors
Abstract To better understand drug resistance mechanisms to CDK4/6 inhibitors and inform precision medicine, we analyze real-world multi-omics data from 400 HR+/HER2- metastatic breast cancer patients treated with CDK4/6 inhibitors plus endocrine therapies, including 200 pre-treatment and 227 post-p...
Saved in:
| Main Authors: | Zhengyan Kan, Ji Wen, Vinicius Bonato, Jennifer Webster, Wenjing Yang, Vladimir Ivanov, Kimberly Hyunjung Kim, Whijae Roh, Chaoting Liu, Xinmeng Jasmine Mu, Jennifer Lapira-Miller, Jon Oyer, Todd VanArsdale, Paul A. Rejto, Jadwiga Bienkowska |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-01-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-025-55914-x |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Identification of breast cancer subtypes and drug response prediction through forward and reverse translation
by: Julie Karam, et al.
Published: (2025-07-01) -
CDK4 inactivation inhibits apoptosis via mitochondria-ER contact remodeling in triple-negative breast cancer
by: Dorian V. Ziegler, et al.
Published: (2025-01-01) -
RET inhibition overcomes resistance to combined CDK4/6 inhibitor and endocrine therapy in ER+ breast cancer
by: Charlotte K. Kindt, et al.
Published: (2025-01-01) -
Er tussen in
by: Theo van der Zee
Published: (2025-07-01) -
JNK pathway suppression mediates insensitivity to combination endocrine therapy and CDK4/6 inhibition in ER+ breast cancer
by: Sarah Alexandrou, et al.
Published: (2025-08-01)